35 results about "Low insulin" patented technology

Disclosed is a strain of Bifidobacterium longum subsp. longum named dipro-O. The Bifidobacterium longum subsp. longum dipro-O used in the present invention has the ability to overproduce BSH, the ability to reduce cholesterol, and the ability to metabolize tryptophan into indole-3-lactic acid, can effectively reduce body weight, significantly lower insulin resistance levels resulting from high-fat diets, reduce the expression of the inflammatory cytokine TNF-α, significantly lower the levels of total cholesterol (TC) and low-density lipoprotein (LDL) in the blood, and increase the level of high-density lipoprotein (HDL), and can ameliorate disorders of the gut microbiome structure. In addition, the strain can also have an ameliorating effect on other lipid metabolism-related diseases such as hyperlipidemia, thereby providing health interventions for the host's body weight, liver, intestinal health, and blood lipid levels. Moreover, pasteurized dipro-O can also have the effect of regulating lipid metabolism, further extending the range of applications of the strain.

This invention is applied in the field of medicine, namely in endocrinology, and can be used in the treatment of type 1 diabetes. The invention proposes a combination containing a dipeptidyl peptidase 4 (DPP-4) inhibitor, a proton pump inhibitor (PP1), and γ-aminobutyric acid or γ-aminobutyric acid receptor agonist. This unique combination and dosage of drugs leads to the regeneration (recovery) of pancreatic β-cells, which occurs with a dramatic reduction in insulin requirements up to a total cessation of insulin in some individuals and is intended for the treatment of type 1 diabetes mellitus.

The invention discloses application of oxidized berberine and berberrubine in treatment of diabetic osteoporosis, and belongs to the technical field of biological medicine. Researches find that both oxidized berberine and berberrubine have the effect of treating diabetic osteoporosis, and can significantly improve the femur microstructure of a diabetic osteoporosis model animal, so that the femur microstructure recovers to a normal level; the blood glucose clearing capacity can be improved, the insulin resistance index is reduced, and the insulin signal channel function is recovered; the oxidative stress state of diabetic osteoporosis model animals can be relieved, the proinflammatory factor level is reduced, and the anti-inflammatory and anti-oxidation effects are achieved. The invention provides a new scheme and data support for the treatment of diabetic osteoporosis, has better curative effect, safety and economy than the prior art, and has important clinical transformation value.

The invention relates to a small-dose automatic metering, subpackaging and storing device and a control method thereof, and relates to the technical field of medical medication configuration and intravenous infusion dosing assistance. The intelligent metering injection unit is arranged in the shell and is used for fixedly mounting a disposable syringe; the piston displacement detection assembly is used for detecting piston displacement in real time; the piston driving and locking mechanism is used for driving the piston of the disposable syringe to automatically shift and be locked at a target dose position; the main control module is used for calculating the actual dose according to the piston displacement; wherein the intelligent metering injection unit provides axial guidance for the disposable syringe, the main control module controls the piston driving and locking mechanism according to the actual dose calculated by the piston displacement detection assembly, and closed-loop metering is achieved. High-precision control over insulin small-dose intravenous dosing can be achieved, the pollution risk caused by pumpback or repeated puncture is avoided, and the actual use loss of insulin injection is reduced on the whole.

The invention discloses an application of TAS2R14 in regulation and control of ADAMTS1 (adenosine monophosphate-adenosine monophosphate) in treatment of insulin resistance. Specifically, the invention provides application of TAS2R14 protein, mRNA or an expression vector thereof, the TAS2R14 protein, the mRNA or the expression vector thereof are used for preparing a preparation or a composition, and the preparation or the composition is used for (a) relieving oxidative stress; (b) reducing insulin resistance (IR). The preparation or composition of the invention effectively reduces insulin resistance and oxidative stress.

The invention is applicable to the technical field of biological medicines, provides application of ophiopogon japonicus borneol glycoside in preparation of a medicine for preventing and treating gestational metabolic diseases, and aims to solve the technical problems that the conventional medicine is limited in use during pregnancy, and the curative effect and the safety are difficult to take into account. According to verification of multi-model systems such as animals, cells and human-derived trophoblast organs, it is found that ophiopogon japonicus borneol glycoside can significantly improve gestational glycometabolism disorder, improve insulin sensitivity and reduce insulin resistance, and therefore effective intervention on gestational diabetes mellitus is achieved. As a natural component derived from the Zhejiang radix ophiopogonis, the radix ophiopogonis borneol glycoside has definite pharmacological activity and excellent safety, and the Zhejiang radix ophiopogonis is listed in a national homology of medicine and food, so that reliable safety guarantee is provided for use during pregnancy.

This invention belongs to the field of biomedical technology and discloses the application of NP in the preparation of a glycemic regulator for aging type 2 diabetes. The NP is a nanoscale complex formed by hydrogen bonding of turtle egg peptide with a molecular weight less than 3 kDa and naringenin at a mass ratio of 100:1. The formulation promotes liver glycogen synthesis and repairs pancreatic tissue structure and pancreatic β-cell function by activating the hepatic IRS1 / PI3K / AKT / GSK-3β signaling pathway and upregulating GLUT2 protein expression. The NP provided by this invention can significantly reduce fasting blood glucose levels in aging type 2 diabetic mice, improve oral glucose tolerance, and reduce the area under the blood glucose curve. Simultaneously, by restoring insulin signal transduction, it significantly reduces the insulin resistance index and improves the insulin sensitivity index, with an improvement level approaching that of the classic hypoglycemic drug metformin.

The present invention relates to modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and / or treating metabolic syndrome utilizing the modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of improving insulin sensitivity and glycemic control, reducing insulin levels and / or improving leptin sensitivity utilizing the modified or polymer conjugated MetAP2 inhibitors.

The invention relates to a nutritional composition. The nutritional composition consists of fucosyllactose, neutral non-fucosyllactose and sialic acid lactose. According to the nutritional composition disclosed by the invention, by additionally supplementing the nutritional composition in daily diet, the insulin sensitivity is further improved and / or the insulin resistance is reduced, so that a synergistic effect is achieved, and the blood glucose homeostasis of pregnant women is improved.

The invention belongs to the technical field of medicines, and discloses synthesis and application of polycholic acid-short chain fatty acid with a novel structure. The polymer is formed by connecting polycholic acid (as a main chain) with one or more short-chain fatty acids through covalent bonds. The polycholic acid is introduced as a skeleton structure of the polymer and the short-chain fatty acid is introduced as a side chain group, so that the functional polymer with biological activity is constructed. The invention also provides a nano-drug prepared by taking the polymer as a carrier. The nano-drug has good biocompatibility and drug loading capacity, effectively improves the effects of losing weight, reducing fat and relieving liver inflammation, effectively relieves liver fibrosis and aging, can enhance the fatty liver treatment effect and further reduce insulin resistance, and has wide clinical application prospects.

Disclosed herein is a method for promoting insulin sensitivity in a subject that involves administering to the subject a therapeutically effective amount of a composition comprising an monocarboxylate transporter 1 (MCT1) inhibitor. For example, the subject can have or be at risk of developing a metabolic disorder characterized by high blood glucose and low insulin levels, e.g., type 2 diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) and atherosclerosis. The subject can also have been diagnosed with cancer cachexia or with a cancer, such as a solid tumor or lymphoma.

The present disclosure relates to a composition containing parsnip extract as an active ingredient which reduces the downregulation of tight junction protein expression, promote the proliferation of beneficial intestinal bacteria, improve the intestinal environment such as maintaining a slightly acidic intestinal environment, and have effects such as reducing intestinal permeability. Therefore, the composition may improve intestinal health and prevent, treat, or improve leaky gut syndrome, and may be used as a material for foods, feeds, pharmaceuticals, or quasi-drugs. Additionally, the composition may have body fat reduction and weight loss activities, reduce the protein expression of lipid metabolism-related factors such as ACC, FAS, SREBP1, ChREBP, G6PD, or C / EBPα, and have effects such as reducing liver weight, reducing blood sugar, reducing ALT or AST levels, reducing insulin resistance, and reducing extent of liver damage. Therefore, the composition may prevent, treat, or improve obesity or a metabolic disease.

The invention belongs to the technical field of biological medicines, and particularly relates to application of EPA (eicosapentaenoic acid) plasmalogen in preparation of medicines for improving or preventing diabetic nephropathy, which is characterized by treating diabetic nephropathy mouse models induced by high fat diet and streptozotocin and having insulin resistance and hyperglycemia accompanied by kidney lipid accumulation and glomerular filtration rate reduction, and particularly relates to application of EPA plasmalogen in preparation of medicines for improving or preventing diabetic nephropathy. The treatment effect of the EPA plasmalogen on the diabetic nephropathy is observed; results show that the EPA plasmalogen has obvious effects of improving kidney functions and kidney ectopic lipid deposition on diabetic nephropathy mice induced by high fat diet and streptozotocin, and also has the effects of reducing blood sugar, improving blood fat, reducing insulin resistance and the like. The EPA plasmalogen is used for intervening the diabetic nephropathy for the first time, and an important basis is provided for clinically treating the diabetic nephropathy by using the EPA plasmalogen.

The present invention relates to a composition effective in treating diabetes and dyslipidemia prepared according to the solid lipid nanotechnology from two natural phytochemical active ingredients: cinnamonaldehyde extracted from the Vietnamese cinnamon and berberine as a bioactive compound extracted from several plants, including a group of shrubs called Berberis. Via testing, all of the composition of the present invention has shown to have low toxicity and great bioavailability, reduced insulin resistance that allows the sugar level in blood to more effectively induce reduction of insulin, hyperglycolysis that aids the body in cellular sugar decomposition, reduced sugar production in the liver, carbohydrate decomposition slowed down in the intestines, and an increasing in the number of beneficial microbes in the intestines. The composition is effective in reducing the total cholesterol level (TC), and non-HDL-cholesterol, and has a tendency to reduce TG level.

The present disclosure relates to antibodies or antigen-binding fragments thereof that bind specifically to the glucagon-like peptide 1 receptor (GLP1R) protein, and methods of use thereof. In various embodiments, the antibodies or antigen-binding fragments thereof are fully human antibodies that bind to GLP1R. In some embodiments, the antibodies or antigen-binding fragments thereof are useful for attenuating GLP1R activity, thus providing a means of treating, preventing, or alleviating a disease, disorder or condition associated with GLP1R in humans. In some embodiments, the antibodies or antigen-binding fragments thereof elevate glucose levels when administered to a subject and thereby treat hypoglycemia, such as post-bariatric hypoglycemia (PBH), by attenuating insulin secretion from pancreatic beta cells and decreasing insulin expression.

The application is a bifunctional cyclic peptide which reduces insulin and does not increase blood sugar but appropriately reduces blood sugar, and belongs to the technical field of biological medicine. 52‑69 The cyclic peptide is obtained by in-vitro modification and reformation on the basis of the original linear short peptide COX The application realizes the seemingly contradictory two aspects of functions, i.e. inhibiting insulin secretion while not increasing blood sugar, and even reducing blood sugar, and the mechanism may be that the sensitivity of the tissue to insulin is improved. We call it a bifunctional peptide. The bifunctional peptide can be used for congenital hyperinsulinemia, insulin resistance, high insulin of obese people, etc. Literature reports that the increase of insulin is the cause of obesity, but for a long time, we cannot reduce weight by reducing insulin because the blood sugar will increase after the reduction of insulin, and high blood sugar is more harmful to health. The cyclic peptide realizes the function of reducing insulin while the blood sugar does not increase, but is reduced, which opens up a new way for weight loss of obesity, and the peptide can be conveniently administered orally in addition to injection. The convenience of use is greatly improved.

The application discloses application of Clostridium cellabutyricum YQ-FP-027T in preparation of an agent for improving obesity, and belongs to the technical field of functional microorganisms, wherein the Clostridium cellabutyricum YQ-FP-027T is preserved in the China General Microbiological Culture Collection Center, and has a biological preservation number of CGMCC No.7.715. The Clostridium cellabutyricum YQ-FP-027T is a subtype of Clostridium cellabutyricum and is one of probiotics; it is verified through animal experiments that the Clostridium cellabutyricum YQ-FP-027T probiotic can improve the related symptoms of obesity induced by high-fat diet, such as reducing body weight, improving glucose tolerance and reducing insulin resistance level.

A method allows people to not compromise on the taste and flavor of sugar-containing foods and beverages, while reducing the net effect of the sugar in the body. The method may include oral consumption of the enzyme alternansucrase to convert up to 90% of consumed sucrose and other carbohydrates into a carbohydrate complex of undigestible or slowly digestible α-1, 3 and α-1, 6 glucan fibers in the gastrointestinal tract. These glucan fibers have the properties of dietary fibers and a degree of polymerization ranging from 3 to greater than 100. The methods may aid in glucose control, reduce insulin resistance and support healthy glucose homeostasis in diabetic and pre-diabetic conditions. It may promote healthy gut bacteria and improve bowel movements to benefit overall digestive health. It may also be applied to obesity control by reducing blood glucose and, through the production of fiber, blood lipid levels, which supports cardiovascular health.

The application discloses a uORF element for regulating chicken insulin receptor expression and application thereof, belongs to the field of molecular biology and genetic engineering, and the nucleotide sequence of the uORF element is shown in any one of SEQ ID NO. 1-2; the application comprises any one of the following: (1) regulating the expression of firefly luciferase in eukaryotic cells; the eukaryotic cells are chicken embryo fibroblasts and chicken preadipocytes; (2) being applied to genetic breeding of chickens, and the genetic breeding is breeding of meat chickens with reduced insulin resistance; (3) application in preparation of a reagent for regulating the expression of chicken insulin receptors. The application can regulate the expression level of INSR, improve insulin sensitivity, and provide material support for research on the mechanism of insulin in regulating blood glucose.

Provided is use of scavenger receptor class A member 3 or a reagent increasing the expression of scavenger receptor class A member 3 in preparing a hypoglycemic product. By means of overexpressing a human-derived SR-A3 gene in hamsters, it was found that the overexpression of the human-derived SR-A3 gene can reduce the plasma glucose concentration, decrease the plasma insulin concentration, improve glucose tolerance, enhance insulin sensitivity, reduce insulin resistance, lower the expression of gluconeogenesis-related genes, and inhibit the activation of the AKT signaling pathway. The present application provides a new target and a new strategy for the precise treatment of patients with hyperglycemia.

The invention discloses an application of GPR110 as a therapeutic target of type 2 diabetes mellitus. The application discovers that the GPR110 gene is used as a therapeutic target of type 2 diabetes for the first time, and provides application of adenovirus-mediated GPR110 gene overexpression in preparation of drugs for treating type 2 diabetes. In an adult type 2 diabetes mouse model db / db, through caudal vein injection of adenovirus-mediated GPR110 overexpression, it is found that the type 2 diabetes related symptoms are significantly improved. The blood glucose level and the fasting blood glucose level are obviously reduced, and an insulin tolerance test (ITT) result shows that the insulin sensitivity is obviously improved. In addition, a decrease in serum insulin level prompts a reduction in pancreatic islet function burden. The results show that the adenovirus-mediated GPR110 overexpression can effectively improve the metabolic disorder of mice with type 2 diabetes mellitus, and a new intervention method and means are provided for the treatment of the type 2 diabetes mellitus.

This invention discloses a device for disinfecting insulin pumps, belonging to the field of insulin pump disinfection technology. It includes a disinfection chamber, a drive mechanism, a circulating motion mechanism, and a cleaning mechanism. The disinfection chamber has an inlet and an outlet on both sides. A feeding chute is located at the inlet on one side of the disinfection chamber, and a discharging chute is located at the outlet on the other side. This device can disinfect the entire surface of the insulin pump, and medical personnel can select the appropriate cleaning effect according to the required level of cleanliness, thus avoiding the limitation of only achieving the best cleaning effect and reducing the disinfection efficiency of the insulin pump during the disinfection process. Simultaneously, it can disinfect multiple insulin pumps at the same time and can also wipe away stains on the display screen and buttons on the surface of the insulin pump, further improving the cleaning and disinfection effect.

Described herein are methods of treating overweight, weight management, treating diabetes, reducing blood glucose, reducing insulin resistance, reducing serum triglyceride levels, and / or reducing adipose weight in a subject, the methods comprising administering an incretin mimetic and an inflammasome modulator to the subject. In some embodiments the method of treatment comprises administering an incretin mimetic and administering a compound of formulae (I), (II), (III), (IV), (V), (V-A), (V-B), (VI), (VII), or (0).

Provided herein are cultivated animal cells that are adapted to grow in growth medium that contains low-insulin or no exogenously provided insulin. Provided herein are cultivated animal cells that are adapted to grow in growth medium that contains low-transferrin or no exogenously provided transferrin. Provided herein are methods of cultivating animal cells in growth medium that contains low-insulin or no exogenously provided insulin. Provided herein are methods of cultivating animal cell in growth medium that contains low-transferrin or no exogenously provided transferrin. Also provided are food products made from cultivated animal cells.

This invention discloses a KDM4C inhibitor and its applications, relating to the field of biomedical technology. Specifically, this invention discloses the application of the KDM4C inhibitor in any of A1) to A5): A1) preparing a drug for the prevention or treatment of obesity; A2) preparing a drug for reducing weight; A3) preparing a drug for reducing food intake; A4) preparing a drug for reducing insulin sensitivity; A5) preparing a drug for enhancing glucose homeostasis. This is achieved through knockout... Kdm4c Inhibiting KDM4C gene activity or inhibiting KDM4C activity can significantly reduce obesity induced by a high-fat diet, thereby regulating the secretion of related hormones / adipokines, affecting food intake, improving insulin resistance, and enhancing insulin sensitivity, making it a potential target for the treatment of obesity.

The present invention relates to the delivery of a composition, preferably a pharmaceutical composition, comprising D-pinitol, D-chiro-inositol or myo-inositol, or any pharmaceutically acceptable salt thereof, for the treatment or prevention of a condition, disease or condition in a subject in need thereof in response to stimulation of a starvation receptor. In particular, for the treatment and / or prevention of conditions responsive to positive modulation (stimulation) of the starvation receptor, such as diabetes, obesity-related conditions, and most preferably for the treatment or prevention of age-related conditions or diseases, such as obesity-related conditions. Enhancing muscle viability or fragility, and treating or preventing sarcopenia, improving cognition (and / or treating or preventing diseases such as Alzheimer's disease, vascular dementia, Parkinson's disease and huntington's disease), for example by promoting appetite, inhibiting insulin secretion and reducing insulin resistance, increasing growth hormone release, by increasing net muscle mass and treating or preventing age-related hypertension.

The invention discloses ice cream radish health-care product soft sweets and a preparation method thereof. The ice cream radish health-care product soft sweets comprise 10-20 parts of a radish extracting solution. Active substances such as glucosinolate and lignin are reserved to the maximum extent by adopting the radish extracting solution and a low-temperature concentration process, the heat clearing and detoxifying effects of the radish powder are improved by 40% compared with those of traditional radish powder, the dietary fiber supplement is compounded by inulin and resistant starch according to the ratio of 1: 1-2: 1, intestinal flora is synergistically improved, the proliferation efficiency of bifidobacteria is improved by two times compared with that of a single component, and the nutritional value of the radish powder is improved. Due to the design of a composite sugar source of white granulated sugar, glucose syrup and resistant starch, the blood glucose generation index of the soft sweets is reduced to 35 or below, the postprandial blood glucose peak value is reduced by 22% compared with that of soft sweets with the same amount of white granulated sugar, functional ingredients are added, intestinal metabolism can be adjusted, the insulin resistance index can be reduced, and the composite vitamin supplement and the active ingredients of the radishes form an antioxidant network, so that the health-care function of the soft sweets is achieved. The lymphocyte proliferation capacity is improved by 25%, and the inflammatory factor IL-6 level is reduced by 37%, so that the novel soft sweet can be well used as a health care product.

This invention relates to the delivery of a composition, preferably a pharmaceutical composition, comprising D-pinitol, D-Chiro inositol or myo-inositol or any pharmaceutically acceptable salt thereof, for use in the treatment or prevention of disorders, diseases or conditions responsive to the stimulation of the ghrelin receptor in a subject in need thereof. In particular, for the treatment and / or prevention of disorders responsive to the positive modulation (stimulation) of the ghrelin receptor, such as diabetes, obesity-related disorders, and, most preferably, for treating or preventing age related conditions or diseases such as by promoting appetite, inhibiting insulin secretion and lowering insulin resistance, increasing growth hormone release, enhancing muscle vitality or fragility and treating or preventing sarcopenia by increasing net muscle mass, improving cognition (and / or treating or preventing diseases such as Azlheimer's disease, vascular dementia, Parkinson's Disease, and Huntington's disease) and treating or preventing age related hypertension.

To provide compositions for use in the treatment and / or prevention of disorders responsive to positive modulation of a ghrelin receptor, such as diabetes, obesity-related disorders, and most preferably for the treatment or prevention of age-related conditions or diseases, for example, by stimulating appetite, inhibiting insulin secretion and lowering insulin resistance, increasing growth hormone release, enhancing muscle vitality or fragility, and the like.SOLUTION: Provided is a composition, pharmaceutical composition, or nutraceutical or food composition, or dietary supplement comprising D-pinitol, D-chiro-inositol and / or myo-inositol, or any salt thereof, for use in preventing or slowing the onset of the clinical manifestations of mild cognitive impairment or in preventing or slowing the onset of the clinical manifestations of a tauopathy in a subject.SELECTED DRAWING: None

The invention provides a composition with hypoglycemic activity and a preparation method and application thereof, and belongs to the technical field of biological medicine. According to the composition disclosed by the invention, cinnamon, turmeric and red ginseng which are homologous in medicine and food are used as core raw materials and are compounded with eggshell membrane extract; after scientific components in parts by weight, all the raw materials achieve synergistic interaction, the inhibition rate on alpha-glucosidase can be remarkably increased, hyperglycemia model rat tests prove that the composition can remarkably reduce the blood sugar concentration, zebra fish tests prove that the composition can remarkably reduce the insulin content and the glucose level, the blood sugar reducing effect is remarkable, and the composition is suitable for clinical application. The traditional Chinese medicine composition can be effectively applied to blood sugar reduction and diabetes treatment. The composition is simple in component, clear in composition, high in raw material safety and free of toxic and side effects, the risk of liver injury possibly caused by combination of multiple traditional Chinese medicines is effectively avoided, and the medication safety and patient compliance are greatly improved.